HRV Pharma buys Germany's Phatebo to enter finished formulations
In short
HRV Pharma has bought Germany’s Phatebo.
The deal helps the Hyderabad company enter Europe’s finished formulations business. The report says Phatebo had ₹350 crore revenue in 2025, but it does not say how much HRV paid.
What the reporting says
Hyderabad-based HRV Pharma acquired German clinical trial supplier Phatebo and is moving into Europe’s finished formulations business. The publisher summary says Phatebo reported ₹350 crore revenue in 2025, but it does not state the deal value or closing terms. The immediate consequence is HRV Pharma’s expansion beyond its existing business, though the integration timeline and strategic rationale beyond market entry were not stated.
Why it matters
HRV Pharma acquired German clinical trial supplier Phatebo, according to a publisher summary, and the move takes HRV into Europe’s finished formulations business. Phatebo reportedly posted ₹350 crore revenue in 2025. The reporting does not disclose the acquisition price, financing, or completion details, so the size and immediate financial impact of the transaction remain unknown.